Simpson A J, Booth N A, Moore N R, Bennett B
Department of Medicine and Therapeutics, University of Aberdeen, Scotland.
Br J Haematol. 1990 Aug;75(4):543-8. doi: 10.1111/j.1365-2141.1990.tb07796.x.
The relative importance and behaviour of plasma and platelet plasminogen activator inhibitor (PAI-1) in disease has not hitherto been examined. In this study the concentration of PAI-1 in the plasma and platelets of patients with a variety of disorders was examined using a specific ELISA and a functional assay. Mean plasma PAI-1 was elevated in groups of patients with diabetes mellitus, hypertension, alcoholic cirrhosis, angina and myocardial infarction. Plasma PAI-1 was raised in the post-operative phase and the PAI-1 released after surgery was not derived from platelets. In all groups PAI-1 in the platelet pool reflected the platelet count, except in type II diabetes mellitus and chronic renal failure, where a reduced quantity of PAI-1 antigen per platelet was found. In severe chronic renal failure, abnormal platelets and diminished platelet PAI-1 may contribute to the haemorrhagic tendency sometimes seen in this disorder. Plasma PAI-1 represents a larger proportion of total circulating PAI-1 in disease than it does in healthy individuals; PAI-1 per platelet is abnormal only in a minority of disorders. Plasma and platelet pools of PAI-1 vary independently in disease and both merit consideration in evaluating the importance, if any, of PAI-1 in thrombosis or haemorrhage.
血浆和血小板纤溶酶原激活物抑制剂（PAI-1）在疾病中的相对重要性和表现迄今尚未得到研究。在本研究中，使用特异性酶联免疫吸附测定法（ELISA）和功能测定法检测了患有各种疾病的患者血浆和血小板中PAI-1的浓度。糖尿病、高血压、酒精性肝硬化、心绞痛和心肌梗死患者组的平均血浆PAI-1升高。术后血浆PAI-1升高，且手术后释放的PAI-1并非来源于血小板。在所有组中，除II型糖尿病和慢性肾衰竭外，血小板池中的PAI-1反映血小板计数，在II型糖尿病和慢性肾衰竭中，发现每个血小板的PAI-1抗原量减少。在严重慢性肾衰竭中，异常血小板和血小板PAI-1减少可能导致该疾病中有时出现的出血倾向。与健康个体相比，疾病状态下血浆PAI-1在总循环PAI-1中所占比例更大；仅在少数疾病中每个血小板的PAI-1异常。疾病状态下血浆和血小板中的PAI-1池独立变化，在评估PAI-1在血栓形成或出血中的重要性（若有）时，两者均值得考虑。
